Repligen Corp (NAS:RGEN)
$ 171.78 -0.16 (-0.09%) Market Cap: 9.60 Bil Enterprise Value: 9.56 Bil PE Ratio: 687.12 PB Ratio: 4.87 GF Score: 94/100

Repligen Corp at JPMorgan Healthcare Conference Transcript

Jan 15, 2020 / 07:30PM GMT
Release Date Price: $99.6 (+0.22%)
Ruizhi Qin
JP Morgan Chase & Co, Research Division - Analyst

Good morning, everyone. I'm Julia Qin. I work on life science tools and diagnostics team here at JPMorgan. And it is my great pleasure to introduce you to our next company presentation today, Repligen. As a reminder, after this session, there is a breakout in the Georgian Room. And with that, I would turn it over to Tony. Welcome.

Anthony J. Hunt
Repligen Corporation - CEO, President, Director & Member of Scientific Advisory Board

Thanks, Julia. Welcome, everybody, and it's great to be here again this year. I just want to thank the JPMorgan team for giving us an opportunity to discuss not only the tremendous progress we made at Repligen in 2019, give you a little bit of insight to what we think is going to happen in 2020, and then talk a little bit about the next 5 years and what we view as the key part of our strategy as we continue to grow and take share in the bioprocessing market.

So I think everybody knows we're now one of the leading players in bioprocessing. If you actually

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot